
Genovis Q2 2025 - Undramatic report but recent developments are case supporting

Redeye updates its view on Genovis' following a Q2 2025 report falling slightly short of our estimates and the recently expanded license agreement with Thermo Fischer which we find supportive to the long-term case.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Genovis Q2 2025 - Undramatic report but recent developments are case supporting](#)